Apotex reportedly considering a sale
Canadian drugmaker Apotex reportedly is exploring a sale. The business, which is valued at roughly $3 billion, is being eyed by some major pharmaceutical companies and investors, according to a Bloomberg report.
According to the report, Apotex is working with a financial adviser as it reviews options that may lead to a partial or full sale of the business.
Sale considerations are preliminary and no final decision has been made on the details of the deal including its structure, the Bloomberg report said.
Founded in 1974, Apotex makes generic and innovative drugs and operates in more than 45 countries including the U.S., Mexico and India.
Last year, Apotex agreed to sell its commercial operations and certain infrastructure in five European countries to Indian drugmaker Aurobindo Pharma for about $83 million.
According to the report, Apotex is working with a financial adviser as it reviews options that may lead to a partial or full sale of the business.
Sale considerations are preliminary and no final decision has been made on the details of the deal including its structure, the Bloomberg report said.
Founded in 1974, Apotex makes generic and innovative drugs and operates in more than 45 countries including the U.S., Mexico and India.
Last year, Apotex agreed to sell its commercial operations and certain infrastructure in five European countries to Indian drugmaker Aurobindo Pharma for about $83 million.